Why Is Dialysis Device And Kidney Care Provider Baxter Stock Trading Higher Today?

Baxter International Inc (NYSE: BAX) posted Q3 revenue of $3.71 billion, which beat the consensus of $3.69 billion, up 3% Y/Y on a reported basis and 2% on a constant currency.

Adjusted EPS of $0.82 surpassed the consensus of $0.67 and the management guidance of $0.78-$0.80. Adjusted EPS from continuing operations stood at $0.68.

Q3 sales performance from continuing operations and, in the aggregate, exceeded Baxter's previously announced guidance, driven by new product launches in Pharmaceuticals, solid demand for Medical Products & Therapies products, and continued improvement in product availability in Healthcare Systems & Technologies. 

Also Read: What's Going On With Kidney Dialysis Provider Stocks Today?

Sales performance in Kidney Care came in better than the company's expectations.

Guidance: Baxter expects Q4 FY23 sales growth from continuing operations of 1%-2% on a reported basis and approximately 1% on a constant currency basis.

Baxter expects Q4 FY23 adjusted EPS from continuing operations of $0.85-$0.88 versus consensus of $0.84.

For FY23, Baxter expects sales growth from continuing operations of 1%-2% on a reported basis and approximately 2% on a constant currency basis.

Baxter expects FY23 adjusted EPS from continuing operations of $2.57-$2.60 versus consensus of $2.59.

Price Action: BAX shares are up 4.48% at $34.26 on the last check Thursday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!